Estrella Immunopharma Reports Nasdaq Minimum Bid Non‑Compliance

What Happened
Estrella Immunopharma, Inc. (ticker: ESLA) filed an 8‑K after receiving a Nasdaq notice on August 17, 2026 that its common stock failed to meet Nasdaq’s $1.00 minimum closing bid requirement. Nasdaq cited a 30‑business‑day stretch where the closing bid was below $1.00 from July 6, 2026 through August 14, 2026. The notice does not immediately affect trading; ESLA will continue to trade on The Nasdaq Capital Market while it attempts to regain compliance.

Key Details

• Nasdaq Letter received: August 17, 2026.
• Deficiency period: closing bid below $1.00 for 30 consecutive business days (July 6 – August 14, 2026).
• Initial compliance period: 180 calendar days, ending February 16, 2027. To cure, ESLA must have a closing bid of at least $1.00 for at least 10 consecutive business days (Nasdaq may require up to 20).
• Company options: may implement a reverse stock split (if used, must be completed no later than 10 business days before Feb 16, 2027). If eligible, ESLA could request a second 180‑day period if all other listing standards (except the minimum bid price) are met. If compliance is not achieved and Nasdaq decides delisting is appropriate, ESLA may appeal to a Nasdaq hearings panel.

Why It Matters
This filing notifies investors that ESLA faces regulatory pressure to raise its share price or take corporate action (for example, a reverse split) to stay listed on Nasdaq. Failure to regain compliance could lead to delisting proceedings, which can reduce investor access and liquidity for the stock. The company says it will monitor the price and evaluate options but provides no assurance it will regain compliance.